In this cohort study of 9714 patients (8535 with mIDC and 1179 with mILC), those with mILC had longer progression-free survival (PFS) and overall survival (OS) than those with mIDC; estrogen receptor positivity and lower tumor grade were associated with longer PFS and OS. This evidence concerns the gene ESR1 and neoplasm.